Tags

Type your tag names separated by a space and hit enter

Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Mov Disord. 2015 May; 30(6):796-804.MD

Abstract

Preclinical animal models implicate serotonin neurons in the pathophysiology of levodopa (l-dopa)-induced dyskinesias in Parkinson's disease (PD), but effective treatment remains elusive. We examined the relationship between serotonin and l-dopa-induced dyskinesias in a pathologically confirmed cohort of PD patients. We obtained brain tissue from 44 PD cases and 17 age-matched controls and assessed monoamine levels and the serotonin and dopamine transporters in the striatum, and the extent of dopaminergic and serotonergic cell preservation in the substantia nigra (SN) and the dorsal raphe nuclei (DRN), respectively. As expected, PD patients demonstrated a severe loss of all dopaminergic markers, including dopamine (P < 0.0001) and the dopamine transporter (P < 0.0001) in the striatum, and dopaminergic neurons (P < 0.001) in the SN, compared with controls. Marked serotonin loss was observed in the caudate (but not putamen) in PD patients compared with controls (P < 0.001), but no difference was found in the levels of the serotonin transporter in the striatum or density of serotonergic neurons in the DRN between these groups, suggesting a functional but not structural change in the serotonergic system in PD. No difference was seen in levels of serotonergic and dopaminergic markers in the striatum between PD patients with and without dyskinesias, or between cases separated according to the clinical severity of their dyskinesias. The absence of a correlation between striatal serotonin markers and the incidence and severity of l-dopa-induced dyskinesias suggests that an intact and functioning serotonergic system is not a risk factor for developing dyskinesias in PD.

Authors+Show Affiliations

Department of Medicine (Neuroscience), Monash University, Melbourne, Australia.The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia.Department of Medicine (Neuroscience), Monash University, Melbourne, Australia. Neurology Department, Alfred Hospital, Melbourne, Australia.Reta Lila Weston Institute, Institute of Neurology, University College London, London, UK.Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, University College London, London, UK.Anatomical Pathology, Alfred Hospital, Melbourne, Australia.Neuroscience Research Australia and University of New South Wales, Sydney, Australia.Reta Lila Weston Institute, Institute of Neurology, University College London, London, UK. Cork University Hospital Neurosciences Department, Cork, Ireland.Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, University College London, London, UK.The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia.Department of Medicine (Neuroscience), Monash University, Melbourne, Australia. Neurology Department, Alfred Hospital, Melbourne, Australia.Department of Medicine (Neuroscience), Monash University, Melbourne, Australia. Neurology Department, Alfred Hospital, Melbourne, Australia.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25649148

Citation

Cheshire, Perdita, et al. "Serotonergic Markers in Parkinson's Disease and Levodopa-induced Dyskinesias." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 30, no. 6, 2015, pp. 796-804.
Cheshire P, Ayton S, Bertram KL, et al. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. Mov Disord. 2015;30(6):796-804.
Cheshire, P., Ayton, S., Bertram, K. L., Ling, H., Li, A., McLean, C., Halliday, G. M., O'Sullivan, S. S., Revesz, T., Finkelstein, D. I., Storey, E., & Williams, D. R. (2015). Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. Movement Disorders : Official Journal of the Movement Disorder Society, 30(6), 796-804. https://doi.org/10.1002/mds.26144
Cheshire P, et al. Serotonergic Markers in Parkinson's Disease and Levodopa-induced Dyskinesias. Mov Disord. 2015;30(6):796-804. PubMed PMID: 25649148.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. AU - Cheshire,Perdita, AU - Ayton,Scott, AU - Bertram,Kelly L, AU - Ling,Helen, AU - Li,Abi, AU - McLean,Catriona, AU - Halliday,Glenda M, AU - O'Sullivan,Sean S, AU - Revesz,Tamas, AU - Finkelstein,David I, AU - Storey,Elsdon, AU - Williams,David R, Y1 - 2015/02/04/ PY - 2014/02/19/received PY - 2014/10/21/revised PY - 2014/10/23/accepted PY - 2015/2/5/entrez PY - 2015/2/5/pubmed PY - 2016/4/8/medline KW - Parkinson's disease KW - dopamine KW - levodopa-induced dyskinesias KW - serotonin KW - striatum SP - 796 EP - 804 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 30 IS - 6 N2 - Preclinical animal models implicate serotonin neurons in the pathophysiology of levodopa (l-dopa)-induced dyskinesias in Parkinson's disease (PD), but effective treatment remains elusive. We examined the relationship between serotonin and l-dopa-induced dyskinesias in a pathologically confirmed cohort of PD patients. We obtained brain tissue from 44 PD cases and 17 age-matched controls and assessed monoamine levels and the serotonin and dopamine transporters in the striatum, and the extent of dopaminergic and serotonergic cell preservation in the substantia nigra (SN) and the dorsal raphe nuclei (DRN), respectively. As expected, PD patients demonstrated a severe loss of all dopaminergic markers, including dopamine (P < 0.0001) and the dopamine transporter (P < 0.0001) in the striatum, and dopaminergic neurons (P < 0.001) in the SN, compared with controls. Marked serotonin loss was observed in the caudate (but not putamen) in PD patients compared with controls (P < 0.001), but no difference was found in the levels of the serotonin transporter in the striatum or density of serotonergic neurons in the DRN between these groups, suggesting a functional but not structural change in the serotonergic system in PD. No difference was seen in levels of serotonergic and dopaminergic markers in the striatum between PD patients with and without dyskinesias, or between cases separated according to the clinical severity of their dyskinesias. The absence of a correlation between striatal serotonin markers and the incidence and severity of l-dopa-induced dyskinesias suggests that an intact and functioning serotonergic system is not a risk factor for developing dyskinesias in PD. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/25649148/Serotonergic_markers_in_Parkinson's_disease_and_levodopa_induced_dyskinesias_ L2 - https://doi.org/10.1002/mds.26144 DB - PRIME DP - Unbound Medicine ER -